The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status.
about
Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysisLeft-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial.Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies.Development and progression of colorectal neoplasia.Panitumumab in Japanese patients with unresectable colorectal cancer: a post-marketing surveillance study of 3085 patients.Subsequent Immunological Mechanisms.
P2860
The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The treatment of colorectal ca ...... tion analysis and EGFR status.
@en
The treatment of colorectal ca ...... tion analysis and EGFR status.
@nl
type
label
The treatment of colorectal ca ...... tion analysis and EGFR status.
@en
The treatment of colorectal ca ...... tion analysis and EGFR status.
@nl
prefLabel
The treatment of colorectal ca ...... tion analysis and EGFR status.
@en
The treatment of colorectal ca ...... tion analysis and EGFR status.
@nl
P2093
P2860
P1476
The treatment of colorectal ca ...... ation analysis and EGFR status
@en
P2093
Andreas Jung
Nicolas Moosmann
Thomas Kirchner
Volker Heinemann
Wolfgang Hiddemann
P2860
P304
P356
10.3238/ARZTEBL.2009.0202
P50
P577
2009-03-20T00:00:00Z